Acquisition by Bryan Cassaday of 120000 shares of Carmell Therapeutics at 0.358 subject to Rule 16b-3
| CTCX Stock | 0.43 0.03 6.52% |
Slightly above 60% of Carmell Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Carmell Therapeutics suggests that many traders are alarmed. Carmell Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Carmell Therapeutics' earnings reports, geopolitical events, and overall market trends.
Carmell |
Filed transaction by Carmell Therapeutics Officer Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Carmell Therapeutics Fundamental Analysis
We analyze Carmell Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Carmell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Carmell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Carmell Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Carmell Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Carmell Therapeutics stock to make a market-neutral strategy. Peer analysis of Carmell Therapeutics could also be used in its relative valuation, which is a method of valuing Carmell Therapeutics by comparing valuation metrics with similar companies.
Peers
Carmell Therapeutics Related Equities
| FTLF | FitLife Brands, | 0.69 | ||||
| CAKE | Cheesecake Factory | 0.04 | ||||
| INGR | Ingredion Incorporated | 0.67 | ||||
| BDL | Flanigans Enterprises | 2.01 | ||||
| VITL | Vital Farms | 2.34 | ||||
| UNFI | United Natural | 2.36 |
Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.